Literature DB >> 22299775

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.

Bill H Chang, Stephanie G Willis, Linda Stork, Stephen P Hunger, William L Carroll, Bruce M Camitta, Naomi J Winick, Brian J Druker, Kirk R Schultz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22299775      PMCID： PMC4290865          DOI： 10.1111/j.1365-2141.2012.09039.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

Authors:  Maurizio Aricò; Martin Schrappe; Stephen P Hunger; William L Carroll; Valentino Conter; Stefania Galimberti; Atsushi Manabe; Vaskar Saha; André Baruchel; Kim Vettenranta; Keizo Horibe; Yves Benoit; Rob Pieters; Gabriele Escherich; Lewis B Silverman; Ching-Hon Pui; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

2.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Nidal Boulos; Heather L Mulder; Christopher R Calabrese; Jeffrey B Morrison; Jerold E Rehg; Mary V Relling; Charles J Sherr; Richard T Williams
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

4.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:  Heike Pfeifer; Barbara Wassmann; Anna Pavlova; Lydia Wunderle; Johannes Oldenburg; Anja Binckebanck; Thoralf Lange; Andreas Hochhaus; Silvia Wystub; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Journal:  Blood       Date:  2007-04-03       Impact factor: 22.113

5.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Susan O'Brien; Deborah Thomas; Stefan Faderl; Dan Jones; Rebecca Garris; Samuel Dara; Jeffrey Jorgensen; Partow Kebriaei; Richard Champlin; Gautam Borthakur; Jan Burger; Alessandra Ferrajoli; Guillermo Garcia-Manero; William Wierda; Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

6.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

7.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Authors:  Yiguo Hu; Yuhua Liu; Shawn Pelletier; Elisabeth Buchdunger; Markus Warmuth; Doriano Fabbro; Michael Hallek; Richard A Van Etten; Shaoguang Li
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

8.  Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Authors:  Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis J Giles; Weiqiang Zhao; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

9.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

10.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Authors:  Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701
  10 in total
  13 in total

Review 1.  Novel agents for the treatment of childhood acute leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Ther Adv Hematol       Date:  2015-04

2.  ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.

Authors:  Michinori Aoe; Akira Shimada; Michiko Muraoka; Kana Washio; Yoshimi Nakamura; Takahide Takahashi; Masahide Imada; Toshiyuki Watanabe; Ken Okada; Ritsuo Nishiuchi; Takako Miyamura; Kosuke Chayama; Misako Shibakura; Megumi Oda; Tsuneo Morishima
Journal:  Int J Hematol       Date:  2014-03-21       Impact factor: 2.490

Review 3.  Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.

Authors:  Sarah K Tasian; Stephen P Hunger
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 4.  Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.

Authors:  Lewis B Silverman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

Review 6.  Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

Review 7.  Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.

Authors:  Fabrizio Tabbò; Marco Pizzi; Peter W Kyriakides; Bruce Ruggeri; Giorgio Inghirami
Journal:  Oncotarget       Date:  2016-05-03

Review 8.  Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.

Authors:  Amy N Sexauer; Sarah K Tasian
Journal:  Front Pediatr       Date:  2017-11-20       Impact factor: 3.418

Review 9.  Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Stephen P Hunger
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

Review 10.  Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Authors:  Federica Saletta; Carol Wadham; David S Ziegler; Glenn M Marshall; Michelle Haber; Geoffrey McCowage; Murray D Norris; Jennifer A Byrne
Journal:  BBA Clin       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.